Antibody-drug conjugate (ADC) has become the standard of treatment for metastatic urothelial cancer. Current trials generally test the combination or sequential use of antibody-drug conjugates with different targets and different chemotherapeutic reagents.
Case description:
We show that in three patients with metastatic urothelial cancer who have progressed on anti-HER2 antibody-drug conjugates, two showed responses when treated with EV (the same monomethyl auristatin E-containing ADC, but with different targets).
Conclusion:
This result showed the therapeutic potential of sequential use of ADC containing the same chemotherapeutic reagents with different targets for metastatic urothelial cancer.
VlachouEJohnsonBAHoffman-CensitsJ.The role of antibody-drug conjugates in urothelial cancer: a review of recent advances in the treatment of locally advanced and metastatic urothelial cancer. Clin Med Insights Oncol2024; 18: 11795549241290787.
2.
PowlesTCsősziTÖzgüroğluM, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol2021; 22: 931-945.
3.
GrivasPPlimackERBalarAV, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): Outcomes in older patients by age and performance status. Eur Urol Oncol2020; 3: 351-359.
4.
PowlesTValderramaBPGuptaS, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New Eng J Med2024; 390: 875-888.
5.
FuZLiSHanS, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther2022; 7: 93.
6.
PowlesTRosenbergJESonpavdeGP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. New Eng J Med2021; 384: 1125-1135.
7.
ShengXWangLHeZ, et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol2024; 42: 1391-402.
8.
ShengXYanXWangL, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res2021; 27: 43-51.
9.
LoriotYPetrylakDPRezazadeh KalebastyA, et al. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol2024; 35: 392-401.
10.
TagawaSTBalarAVPetrylakDP, et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol2021; 39: 2474-2485.
11.
Meric-BernstamFMakkerVOakninA, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol2024; 42: 47-58.
12.
ChenMHuangRChenR, et al. Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance. Oncologist2024; 29: e957-e66.
13.
McGregorBASonpavdeGPKwakL, et al. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol2024; 35: 91-97.
14.
FuZGaoCWuT, et al. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience2023; 26: 107778.
